MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Vaxart Inc

Fechado

0.32 -23.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.32

Máximo

0.32

Indicadores-chave

By Trading Economics

Rendimento

-3.6M

-16M

Vendas

5.7M

21M

Margem de lucro

-74.684

Funcionários

105

EBITDA

-3.6M

-12M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+1400% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

7.4M

100M

Abertura anterior

24.13

Fecho anterior

0.32

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Vaxart Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de jul. de 2025, 21:01 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 20:46 UTC

Ganhos

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 de jul. de 2025, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 20:36 UTC

Ganhos

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 de jul. de 2025, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 de jul. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 20:02 UTC

Conversa de Mercado

Gold Higher to Close Out Week -- Market Talk

18 de jul. de 2025, 19:14 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 de jul. de 2025, 19:06 UTC

Conversa de Mercado

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 de jul. de 2025, 18:24 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 de jul. de 2025, 18:19 UTC

Ganhos

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 de jul. de 2025, 18:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 de jul. de 2025, 18:11 UTC

Ganhos

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 de jul. de 2025, 17:35 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 de jul. de 2025, 16:29 UTC

Conversa de Mercado

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 de jul. de 2025, 16:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 16:04 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 de jul. de 2025, 15:47 UTC

Conversa de Mercado
Ganhos

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparação entre Pares

Variação de preço

Vaxart Inc Previsão

Preço-alvo

By TipRanks

1400% parte superior

Previsão para 12 meses

Média 6 USD  1400%

Máximo 8 USD

Mínimo 4 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Vaxart Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.4007 / 0.4252Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.